CEO Sabrina Martucci Johnson awarded 172,000 Dare Bioscience (DARE) options

Rhea-AI Filing Summary

Dare Bioscience, Inc. reported that Chief Executive Officer and director Sabrina Martucci Johnson received an employee stock option grant covering 172,000 shares of common stock on January 30, 2026. The option has an exercise price of $1.81 per share and was granted at a price of $0 per option.

The option vests in 48 equal monthly installments, beginning on the one-month anniversary of the grant date, as long as she continues to provide service to the company. After this grant, she directly holds 172,000 such derivative securities.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

JOHNSON SABRINA MARTUCCI

(Last) (First) (Middle)

3655 NOBEL DRIVE

SUITE 260

(Street)

SAN DIEGO CA 92122

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Dare Bioscience, Inc. [ DARE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chef Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/30/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$1.81	01/30/2026		A		172,000		(1)	01/30/2036	Common stock	172,000	$0	172,000	D

Explanation of Responses:

1. This stock option vests and becomes exercisable in 48 equal monthly installments commencing on the one-month anniversary of the grant date, subject to the reporting person's continuous service to the issuer.

Remarks:

	/s/ Sabrina Martucci Johnson	02/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Dare Bioscience (DARE) report in this Form 4?

Dare Bioscience reported an employee stock option grant to CEO and director Sabrina Martucci Johnson for 172,000 shares of common stock, exercisable at $1.81 per share, awarded at no cost on January 30, 2026, and held directly after the transaction.

How many Dare Bioscience (DARE) stock options were granted to the CEO?

Sabrina Martucci Johnson received 172,000 employee stock options linked to Dare Bioscience common stock. These derivative securities give her the right to buy 172,000 shares at a fixed $1.81 exercise price, subject to vesting over time and continued service with the company.

What is the exercise price of the Dare Bioscience (DARE) stock options granted?

The employee stock options granted to Sabrina Martucci Johnson have an exercise price of $1.81 per share. This means she can purchase Dare Bioscience common stock at $1.81 once the options vest, regardless of the market price at that time, subject to plan terms.

How do the Dare Bioscience (DARE) CEO’s options vest over time?

The stock options vest in 48 equal monthly installments starting one month after the January 30, 2026 grant date. Vesting continues only while Sabrina Martucci Johnson maintains continuous service to Dare Bioscience, gradually increasing the number of exercisable options each month.

When do the Dare Bioscience (DARE) stock options granted to the CEO expire?

The employee stock options granted to Sabrina Martucci Johnson expire on January 30, 2036. Until that expiration date, any vested portion of the 172,000 options can be exercised at the fixed $1.81 per share exercise price, subject to the applicable plan and agreement terms.

Is the Dare Bioscience (DARE) CEO’s stock option ownership direct or indirect?

The reported 172,000 employee stock options are held directly by Sabrina Martucci Johnson. The filing lists the ownership form for these derivative securities as “D” for direct, with no separate nature of indirect beneficial ownership disclosed in the provided information.